Elicio Therapeutics to Showcase Innovations at Global Conference
![Elicio Therapeutics to Showcase Innovations at Global Conference](https://investorshangout.com/images/blog/ihnews-Elicio%20Therapeutics%20to%20Showcase%20Innovations%20at%20Global%20Conference.jpg)
Elicio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Elicio Therapeutics, Inc. (Nasdaq: ELTX), a pioneering clinical-stage biotechnology company, is set to make an important presentation at the highly anticipated H.C. Wainwright 26th Annual Global Investment Conference. Robert Connelly, the Chief Executive Officer of Elicio, will take the stage to share insights about the company’s innovative approach to immunotherapy in the treatment of cancer.
Event Details
Scheduled for September 11, 2024, at 2:30 p.m. ET, this conference serves as a platform for investors and stakeholders to gain a deeper understanding of Elicio’s advancements in cancer treatment. The presentation will be accessible via Webcast for those who register, allowing attendees to experience first-hand the developments within Elicio’s promising pipeline. In addition, a replay of the event will be available on-demand for 90 days following the conference.
About Elicio Therapeutics
Elicio Therapeutics is at the forefront of developing groundbreaking lymph node-targeted immunotherapies. Their innovative approach focuses on utilizing the body’s immune system to fight cancer more effectively. The company's pipeline includes several promising therapeutic cancer vaccines designed to target specific mutations associated with aggressive forms of cancer.
Innovative Immunotherapy Solutions
The core technology underpinning Elicio’s advancements is their proprietary AMP technology. This technology enables the precise delivery of therapeutic agents directly to lymph nodes, thereby optimizing the immune response against tumor cells. By enhancing the natural pathways within these critical sites in the immune system, Elicio aims to produce a more robust and sustained immune attack on cancer.
Research and Development Pipeline
Elicio's research pipeline features several promising candidates in immunotherapy. Among these, ELI-002 is notable for targeting mKRAS-driven cancers, whereas ELI-007 and ELI-008 focus on BRAF-driven cancers and p53 hotspot mutations, respectively. Each of these therapies has the potential to significantly improve outcomes for patients suffering from some of the most challenging cancer types.
Future Prospects
As a company at the cutting edge of clinical biopharmaceutical advancements, Elicio Therapeutics is dedicated to fostering innovations that align with the evolving landscape of cancer treatment. With ongoing research and development efforts, the company is committed to delivering its innovative therapies to those in need. Investors and the medical community alike are keenly interested in their upcoming presentations regarding the effectiveness of these therapies.
Investor Relations and Contact Information
For inquiries related to investor relations, Brian Piekos can be contacted directly at Elicio Therapeutics. Interested parties can reach out via email at IR@elicio.com or by telephone at 857-209-0153.
Frequently Asked Questions
What is the significance of Elicio's upcoming presentation?
The presentation will provide insights into Elicio's immunotherapy research and its potential impact on cancer treatment.
When and where will the presentation take place?
The presentation is scheduled for September 11, 2024, during the H.C. Wainwright 26th Annual Global Investment Conference.
What technologies does Elicio utilize in its therapies?
Elicio uses AMP technology to deliver therapeutic agents directly to the lymph nodes, enhancing the immune system's response to cancer.
What cancers do Elicio's therapeutic vaccines target?
Elicio's vaccines focus on targeting aggressive cancers, specifically mKRAS-driven and BRAF-driven cancers, as well as p53 hotspot mutations.
How can investors learn more about Elicio's developments?
Investors can access additional information through the company's investor relations contact, Brian Piekos, via IR@elicio.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Coiled Tubing Market to Reach $6.5 Billion Driven by Innovation
- Challenges and Advances in Sickle Cell Disease Treatments
- FFW Corporation Declares $0.30 Quarterly Dividend
- NewtekOne, Inc. CEO Barry Sloane to Attend Key Conference
- AUGA group, AB Investor Conference Webinar Details
- Public Opening Position Disclosure by Rathbones Group Plc
- Loupe Offers Exciting Rewards for Topps Chrome Basketball
- DCHFA Relaunches ReMIT Program to Assist Seniors
- RealManage Achieves 2024 Great Place to Work Certification
- Maternal Nutrition Products Market Set to Reach $38.66 Billion